Literature DB >> 30082387

Disrupting a negative feedback loop drives endocrine therapy-resistant breast cancer.

Charles E Foulds1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30082387      PMCID： PMC6099889          DOI： 10.1073/pnas.1811263115

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN： 0027-8424            Impact factor:   11.205


× No keyword cloud information.
  19 in total

Review 1.  Biological determinants of endocrine resistance in breast cancer.

Authors:  Elizabeth A Musgrove; Robert L Sutherland
Journal:  Nat Rev Cancer       Date:  2009-09       Impact factor: 60.716

2.  Allele-Specific Chromatin Recruitment and Therapeutic Vulnerabilities of ESR1 Activating Mutations.

Authors:  Rinath Jeselsohn; Johann S Bergholz; Matthew Pun; MacIntosh Cornwell; Weihan Liu; Agostina Nardone; Tengfei Xiao; Wei Li; Xintao Qiu; Gilles Buchwalter; Ariel Feiglin; Kayley Abell-Hart; Teng Fei; Prakash Rao; Henry Long; Nicholas Kwiatkowski; Tinghu Zhang; Nathanael Gray; Diane Melchers; Rene Houtman; X Shirley Liu; Ofir Cohen; Nikhil Wagle; Eric P Winer; Jean Zhao; Myles Brown
Journal:  Cancer Cell       Date:  2018-02-12       Impact factor: 31.743

3.  An estrogen receptor mutant with strong hormone-independent activity from a metastatic breast cancer.

Authors:  Q X Zhang; A Borg; D M Wolf; S Oesterreich; S A Fuqua
Journal:  Cancer Res       Date:  1997-04-01       Impact factor: 12.701

Review 4.  High-throughput functional genomics using CRISPR-Cas9.

Authors:  Ophir Shalem; Neville E Sanjana; Feng Zhang
Journal:  Nat Rev Genet       Date:  2015-04-09       Impact factor: 53.242

Review 5.  Unraveling the mechanisms of endocrine resistance in breast cancer: new therapeutic opportunities.

Authors:  Suleiman Massarweh; Rachel Schiff
Journal:  Clin Cancer Res       Date:  2007-04-01       Impact factor: 12.531

Review 6.  ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer.

Authors:  Rinath Jeselsohn; Gilles Buchwalter; Carmine De Angelis; Myles Brown; Rachel Schiff
Journal:  Nat Rev Clin Oncol       Date:  2015-06-30       Impact factor: 66.675

Review 7.  Challenges in the management of advanced, ER-positive, HER2-negative breast cancer.

Authors:  Christopher D Hart; Ilenia Migliaccio; Luca Malorni; Cristina Guarducci; Laura Biganzoli; Angelo Di Leo
Journal:  Nat Rev Clin Oncol       Date:  2015-05-26       Impact factor: 66.675

Review 8.  Aromatase inhibitors in the breast cancer clinic: focus on exemestane.

Authors:  Kathleen Van Asten; Patrick Neven; Anneleen Lintermans; Hans Wildiers; Robert Paridaens
Journal:  Endocr Relat Cancer       Date:  2014-01-16       Impact factor: 5.678

Review 9.  Enhancing Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer: Cotargeting Signaling Pathways.

Authors:  Stephen R D Johnston
Journal:  J Natl Cancer Inst       Date:  2015-08-06       Impact factor: 13.506

Review 10.  Regulation of the SRC family kinases by Csk.

Authors:  Masato Okada
Journal:  Int J Biol Sci       Date:  2012-11-01       Impact factor: 6.580
View more
  2 in total

1.  Tumor-Associated Macrophages Induce Endocrine Therapy Resistance in ER+ Breast Cancer Cells.

Authors:  Andrés M Castellaro; María C Rodriguez-Baili; Cecilia E Di Tada; Germán A Gil
Journal:  Cancers (Basel)       Date:  2019-02-06       Impact factor: 6.639

2.  Comparative transcriptome analysis between patient and endometrial cancer cell lines to determine common signaling pathways and markers linked to cancer progression.

Authors:  Madelaine J Cho-Clark; Gauthaman Sukumar; Newton Medeiros Vidal; Sorana Raiciulescu; Mario G Oyola; Cara Olsen; Leonardo Mariño-Ramírez; Clifton L Dalgard; T John Wu
Journal:  Oncotarget       Date:  2021-12-21
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.